The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Field...

Key Takeaways: CEO Jason Yang has increased his CStone stake multiple times over the past 18 months to 4.79% of outstanding ...

ZL-1310 is an innovative ADC targeting DLL3, a promising therapeutic target in small cell lung cancer and other DLL3+ solid t...

- Findings will be shared in oral presentations at the 2024 Congress of the European Society of Gynaecological Oncology (ESGO) ...

Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and lowers the price target from $123 to $66.

Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.86) by ...

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

-8-K

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Da...